A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A PHASE2 clinical study on Solid Tumor, this trial is completed. The trial is conducted by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and has accumulated 7 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- PharmaMar
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bengaluru, India , Brussels, Belgium , Charlotte, United States , Edegem, Belgium , Lyon, France , Marseille, France , Miami, United States , Montpellier, France , Moscow, Russia , PAU de Sanchinarro, Spain and 7 more locations